GlassScriptPhysician profile
Ayda Dashtaei
NPI 1497146120
$26,857.57
in general payments reported to CMS, 2019-2025
20 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $16K · 2021: $3,629 · 2022: $3,568 · 2023: $223 · 2024: $1,337 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998 · Travel and Lodging: $886 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.21 |
| Travel and Lodging | $885.51 |
| Education | $137.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $22,620.54 | 2020-2024 | |
| Medical Device Business Services, INC. | $1,052.76 | 2019 | |
| Hologic INC | $885.51 | 2024 | Localizer, Biozorb |
| Boston Scientific Corporation | $496.62 | 2021-2022 | |
| Janssen Biotech, INC. | $356.19 | 2021-2023 | Symtuza |
| Davol INC. | $337.28 | 2024-2025 | Phasix Mesh |
| Myriad Genetic Laboratories, INC. | $249.76 | 2023-2024 | Myrisk, Precisetumor |
| Merck Sharp & Dohme LLC | $226.39 | 2020-2023 | Zerbaxa, Recarbrio, Dificid |
| Medtronic, INC. | $171.55 | 2025 | Plasmablade(Tm) |
| Melinta Therapeutics, LLC | $125.95 | 2020-2023 | Kimyrsa |
| Ethicon US, LLC | $108.81 | 2019 | |
| Csl Behring | $42.27 | 2019 | |
| Solventum Corporation | $32.95 | 2025 | Prevena |
| Viiv Healthcare Company | $25.21 | 2021 | |
| Integra Lifesciences Corporation | $23.50 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $22.40 | 2024 | Spy-Phi System |
| Shionogi INC | $22.37 | 2022 | |
| La Jolla Pharmaceutical Company | $22.26 | 2021 | |
| Allergan, INC. | $20.14 | 2020 | |
| Bard Peripheral Vascular, INC. | $15.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayda Dashtaei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.